Motavizumab

Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research[1].

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> RSV

Motavizumab shows activity after F protein initiates interaction with the cell membrane and before virus transcription[2]. Motavizumab inhibits F protein-mediated cell-to-cell fusion[2].

Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice[1]. Animal Model: Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2[1] Dosage: 1.25 mg in 0.1 ml of PBS/per mouse Administration: Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once Result: Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5. Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice.

[1]. Mejías A, et al. Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model. Virol J. 2007 Oct 25;4:109.

[2]. Huang K, et al. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol. 2010 Aug;84(16):8132-40.